Evaluation of the Drug-Polymer Compatibility and Dissolution Behaviour of Fenbendazole-Soluplus

Amirhossein Karimi, Gilberto S N Bezerra, Clement L Higginbotham, John G Lyons

Abstract read

In one paragraph

Article in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amirhossein KarimiThe PRISM Research Institute, Technological University of the Shannon: Midlands Midwest, Athlone Campus, University Road, N37 HD68 Athlone, Co. Westmeath, Ireland.ORCID 0000-0003-2161-3124

Gilberto S N BezerraDepartment of Life and Sciences, Dundalk Institute of Technology, N37 HD68 Dundalk, Co. Louth, Ireland.ORCID 0000-0001-7434-3223

Clement L HigginbothamThe PRISM Research Institute, Technological University of the Shannon: Midlands Midwest, Athlone Campus, University Road, N37 HD68 Athlone, Co. Westmeath, Ireland.ORCID 0000-0001-8100-6276

John G LyonsThe PRISM Research Institute, Technological University of the Shannon: Midlands Midwest, Athlone Campus, University Road, N37 HD68 Athlone, Co. Westmeath, Ireland.ORCID 0000-0003-1998-070X

Funding

Technological University of the Shannon Presidents Doctoral Scholarship

6 · The paper itself

Abstract

Fenbendazole is an important anti-parasitic medicine widely used in the veterinary field and has recently been considered as a possible anti-cancer agent in humans by some researchers. Fenbendazole encounters challenges in its usage due to its limited aqueous solubility, which consequently impacts its therapeutic efficacy. In this work, an in vitro mechanistic investigation was conducted to evaluate the compatibility, amorphization behaviour and dissolution profile of fenbendazole dispersed in Soluplus

Indexed as

fenbendazolehot-melt extrusionsolid dispersionsolubility enhancementSoluplus®

Identifiers

PMID41682042

DOI10.3390/polym18030333

PMCPMC12899570

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.